All participating institutions should establish procedures for complete casefinding within their institution. In many hospitals, records are housed in one location (i.e., the medical records department). In others, procedures for identifying patients from multiple independent ancillary service areas may be necessary (i.e., outpatient clinics, radiation therapy, etc). It is important that the following multiple sources in the hospital be searched to keep missed reportable cases to a minimum. The procedures outlined below should be adapted to each individual hospital.
1. Medical record disease discharge diagnostic index:
Any patient record coded with the diagnoses listed below should be reviewed to determine if the case is one which meets KCR reportability criteria. Note that a diagnosis is not necessarily reportable simply because it falls within the codes below; refer to the Case Reportability Requirements to make sure the case is truly reportable to KCR.
ICD-10-CM Codes (Effective 10-01-2023 through 09-30-2024) PDF: icd-10-cm-casefinding-list.20231005.pdf Excel: icd-10-cm-casefinding-list.20231005.xlsx
ICD-10-CM Codes (Effective 10-01-2022 through 09-30-2023) PDF:
ICD-10-CM Codes (Effective 10-01-2021 through 09-30-2022)
ICD-10-CM Codes (Effective 10-01-2020 through 09-30-2021)
ICD-10-CM Code | Explanation of Code |
C00.- - C43.-, C4A.-, C45.- - C48.-, C49.- -C96.- | Malignant neoplasms (excluding category C44 and C49.A), stated or presumed to be primary (of specified site) and certain specified histologies Note: The following neoplasm codes are new for FY2022 (10/1/2021) C56.3: Malignant neoplasm of bilateral ovaries C79.63: Secondary malignant neoplasm of bilateral ovaries C84.7A: Anaplastic large cell lymphoma, ALK-negative, breast |
C44.00, C44.09 | Unspecified/other malignant neoplasm of skin of lip |
C44.10-, C44.19- | Unspecified/other malignant neoplasm of skin of eyelid |
C44.13- | Sebaceous cell carcinoma of skin of eyelid, including canthus |
C44.20-, C44.29- | Unspecified/other malignant neoplasm skin of ear and external auricular canal |
C44.30-, C44.39- | Unspecified/other malignant neoplasm of skin of other/unspecified parts of face |
C44.40, C44.49 | Unspecified/other malignant neoplasm of skin of scalp & neck |
C44.50-, C44.59- | Unspecified/other malignant neoplasm of skin of trunk |
C44.60-, C44.69- | Unspecified/other malignant neoplasm of skin of upper limb, incl. shoulder |
C44.70-, C44.79- | Unspecified/other malignant neoplasm of skin of lower limb, including hip |
C44.80, C44.89 | Unspecified/other malignant neoplasm of skin of overlapping sites of skin |
C44.90, C44.99 | Unspecified/other malignant neoplasm of skin of unspecified sites of skin |
C49.A- | Gastrointestinal Stromal Tumors Note: All GIST tumors are now reportable starting in 2021 (per ICD-O-3.2), including GIST, NOS |
D00.- - D05.-, D07.- - D09 | In-situ neoplasms Note 1: Excludes carcinoma in situ tumors of the cervix (D06._) Note 2: Excludes prostatic intraepithelial neoplasia (PIN III) (8148/2) of the prostate. Other prostate in situ histologies are reportable Note 3: For D04 (carcinoma in situ of skin), excludes basal and squamous cell in situ lesions |
D13.7 | Benign neoplasm of endocrine pancreas Note: Effective 1/1/2021: Review this code to look for the following which were previously a benign tumor of the pancreas, but is now malignant per ICD-O-3.2 • Islet cell adenoma • Nesidioblastoma • Islet cell adenomatosis • Insulinoma • Beta cell adenoma |
D18.02 | Hemangioma of intracranial structures and any site |
D21.4, D48.1 | Benign neoplasm of connective and other soft tissue of abdomen Note: Effective 1/1/2021: Review this code to look for the following which were previously a benign tumor of the pancreas, but is now malignant per ICD-O-3.2 • Gastrointestinal stromal tumor, NOS/GIST, NOS/Gastrointestinal autonomic nerve tumor/GANT/Gastrointestinal pacemaker cell tumor (8936/1, now 8936/3) |
D23.9 | Other benign neoplasm of skin Benign carcinoid tumors of other sites Note: Effective 1/1/2021: Review these code to look for the following which were previously benign and borderline tumors, but are now malignant per ICD-O-3.2 • Aggressive digital papillary adenoma (c44_) (8408/1, but now 8408/3) |
D3A._ | Benign carcinoid tumors of other sites Note: Effective 1/1/2021: Review these codes to look for the following which were previously benign and borderline tumors, but are now malignant per ICD-O-3.2 • Carcinoid tumor, argentaffinoma, NOS (8240/1, now 8241/3) • Enterochromaffin-like cell carcinoid, NOS (8242/1, now 8241/3) |
D32.- | Benign neoplasm of meninges (cerebral, spinal and unspecified) |
D33.- | Benign neoplasm of brain and other parts of central nervous system |
D35.00 - D35.02 | Benign neoplasm of adrenal gland Note: Effective 1/1/2021: Review this code to look for the following which was previously a benign (8700/0) tumor of the adrenal gland, but is now malignant per ICD-O-3.2 (8700/3) • Pheochromocytoma • Adrenal medullary paraganglioma • Chromaffin paraganglioma • Chromaffin tumor • Chromaffinoma |
D35.2 - D35.4 | Benign neoplasm of pituitary gland, craniopharyngeal duct and pineal gland |
D37.8 | Neoplasm of uncertain behavior of other specified digestive organs (includes uncertain behavior of pancreas) Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2 • Pancreatic endocrine tumor, NOS (C259, 8150/1, now 8150/3) • Islet cell tumor, NOS (C259, 8150/1, now 8150/3) • Glucagonoma, NOS (C259, 8152/1, now 8152/3) • Alpha cell tumor, NOS (C259, 8152/1, now 8152/3) • Glucagon-like peptid-producing tumor (C259, 8152/1, now 8152/3) • Somastostatinoma, NOS (8156/1, now 8156/3) • Somatostatin cell tumor, NOS (8156/1, now 8156/3) • Endocrine tumor, functioning, NOS (8158/1, now 8158/3) • ACTH-producing tumor (8158/1, now 8158/3) |
D42.-, D43.- | Neoplasm of uncertain or unknown behavior of meninges, brain, CNS |
D44.3 - D44.5 | Neoplasm of uncertain or unknown behavior of pituitary gland, craniopharyngeal duct and pineal gland |
D44.6 | Neoplasm of uncertain behavior of carotid body Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2 • Carotid body tumor/Carotid body paraganglioma (8692/1, now 8692/3) |
D44.7 | Neoplasm of uncertain behavior of aortic body and other paraganglia Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2 • Paraganglioma, NOS (8680/1, now 8680/3) • Sympathetic paraganglioma (8681/1, now 8681/3) • Parasympathetic paraganglioma (8682/1, now 8682/3) • Glomulus jugulare tumor, NOS/jugular paraganglioma/juglotympanic paraganglioma (8690/1, now 8690/3) • Aortic body tumor/aortic body paraganglioma/aorticopulmonary paraganglioma (8691/1, now 8691/3) • Extra-adrenal paraganglioma, NOS/nonchromaffin paraganglioma, NOS/chemodectoma (8693/1, now 8693/3) |
D45 | Polycythemia vera (9950/3) ICD-10-CM Coding instruction note: Excludes familial polycythemia (C75.0), secondary polycythemia (D75.1) |
D46.- | Myelodysplastic syndromes (9980, 9982, 9983, 9985, 9986, 9989, 9993) |
D47.02 | Systemic mastocytosis |
D47.1 | Chronic myeloproliferative disease (9963/3, 9975/3) ICD-10-CM Coding instruction note: Excludes the following: Atypical chronic myeloid leukemia BCR/ABL-negative (C92.2_) Chronic myeloid leukemia BCR/ABL-positive (C92.1_) Myelofibrosis & Secondary myelofibrosis (D75.81) Myelophthisic anemia & Myelophthisis (D61.82) |
D47.3 | Essential (hemorrhagic) thrombocythemia (9962/3) Includes: Essential thrombocytosis, idiopathic hemorrhagic thrombocythemia |
D47.4 | Osteomyelofibrosis (9961/3) Includes: Chronic idiopathic myelofibrosis Myelofibrosis (idiopathic) (with myeloid metaplasia) Myelosclerosis (megakaryocytic) with myeloid metaplasia) Secondary myelofibrosis in myeloproliferative disease |
D47.9 | Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9970/1, 9931/3) |
D47.Z- | Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9960/3, 9970/1, 9971/3, 9931/3) Note: Effective 1/1/2021, PTLD (9971/3) is no longer reportable (9971/1) |
D48.0 | Neoplasm of uncertain behavior of bone and articular cartilage Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2 • Clear cell odontogenic tumor (9341/1, now 9341/3) |
D49.2 | Neoplasm of unspecified behavior of digestive organs (includes unspecified behavior of pancreas)Note: Review this code to look for the following which were previously unknown behavior tumors of the pancreas, but are now malignant tumors per ICD-O-3.2 (Histology 8150/3) • Pancreatic endocrine tumor, NOS • Islet cell tumor, NOS |
D49.6, D49.7 | Neoplasm of unspecified behavior of brain, endocrine glands and other CNS |
D72.110 | Hypereosonophilic syndrome [HES] (9964/3) Effective 10/1/2020 Note: Previous code (FY 2015- FY 2020): D72.1: Eosinophilia |
D72.111 | Lymphocytic Variant Hypereosonophilic Syndrome [LHES] (9964/3) Effective 10/1/2020 Note: Previous code (FY 2015- FY 2020): D72.1: Eosinophilia Syndrome [LHES] |
D72.118 | Other Hypereosonophilic syndrome (9964/3) Effective 10/1/2020 Note: Previous code (FY 2015- FY 2020): D72.1: Eosinophilia |
D72.119 | Hypereosonophilic syndrome (9964/3) Effective 10/1/2020 Note: Previous code (FY 2015- FY 2020): D72.1: Eosinophilia |
K31.A22 | Gastric intestinal metaplasia with high grade dysplasia |
R85.614 | Cytologic evidence of malignancy on smear of anus |
R87.614 | Cytologic evidence of malignancy on smear of cervix |
R87.624 | Cytologic evidence of malignancy on smear of vagina |
ICD-10-CM Codes (Effective 10-01-2020 through 09-30-2021)
| ICD-10-CM Code | Explanation of Code | |
|---|---|---|
| C00.- - C43.-, C4A.-, C45.- - C48.-, C49.--C96.- | Malignant neoplasms (excluding category C44 and C49.A), stated or presumed to be primary (of specified site) and certain specified histologies | |
| C44.00, C44.09 | Unspecified/other malignant neoplasm of skin of lip | |
| C44.10-, C44.19- | Unspecified/other malignant neoplasm of skin of eyelid | |
| C44.13- | Sebaceous cell carcinoma of skin of eyelid, including canthus Note: Effective 10/1/2018 | |
| C44.20-, C44.29- | Unspecified/other malignant neoplasm skin of ear and external auricular canal | |
| C44.30-, C44.39- | Unspecified/other malignant neoplasm of skin of other/unspecified parts of face | |
| C44.40, C44.49 | Unspecified/other malignant neoplasm of skin of scalp & neck | |
| C44.50-, C44.59- | Unspecified/other malignant neoplasm of skin of trunk | |
| C44.60-, C44.69- | Unspecified/other malignant neoplasm of skin of upper limb, incl. shoulder | |
| C44.70-, C44.79- | Unspecified/other malignant neoplasm of skin of lower limb, including hip | |
| C44.80, C44.89 | Unspecified/other malignant neoplasm of skin of overlapping sites of skin | |
| C44.90, C44.99 | Unspecified/other malignant neoplasm of skin of unspecified sites of skin | |
| C49.A- | Gastrointestinal Stromal Tumors Note: GIST is only reportable when it is malignant (/3). GIST, NOS (not stated whether malignant or benign) is a /1 and is not reportable. | |
| D00.- - D09.- | In-situ neoplasms Note: Carcinoma in situ of the cervix (CIN III-8077/2) and Prostatic Intraepithelial Carcinoma (PIN III-8148/2) are not reportable | |
| D18.02 | Hemangioma of intracranial structures and any site | |
| D32.- | Benign neoplasm of meninges (cerebral, spinal and unspecified) | |
| D33.- | Benign neoplasm of brain and other parts of central nervous system | |
| D35.2 - D35.4 | Benign neoplasm of pituitary gland, craniopharyngeal duct and pineal gland | |
| D42.-, D43.- | Neoplasm of uncertain or unknown behavior of meninges, brain, CNS | |
| D44.3 - D44.5 | Neoplasm of uncertain or unknown behavior of pituitary gland, craniopharyngeal duct and pineal gland | |
| D45 | Polycythemia vera (9950/3) ICD-10-CM Coding instruction note: Excludes familial polycythemia (C75.0), secondary polycythemia (D75.1) | |
| D46.- | Myelodysplastic syndromes (9980, 9982, 9983, 9985, 9986, 9989, 9991, 9992) | |
| D47.02 | Systemic mastocytosis | |
| D47.1 | Chronic myeloproliferative disease (9963/3, 9975/3) ICD-10-CM Coding instruction note: Excludes the following: Atypical chronic myeloid leukemia BCR/ABL-negative (C92.2_) Chronic myeloid leukemia BCR/ABL-positive (C92.1_) Myelofibrosis & Secondary myelofibrosis (D75.81) Myelophthisic anemia & Myelophthisis (D61.82) | |
| D47.3 | Essential (hemorrhagic) thrombocythemia (9962/3) Includes: Essential thrombocytosis, idiopathic hemorrhagic thrombocythemia | |
| D47.4 | Osteomyelofibrosis (9961/3) Includes: Chronic idiopathic myelofibrosis Myelofibrosis (idiopathic) (with myeloid metaplasia) Myelosclerosis (megakaryocytic) with myeloid metaplasia) Secondary myelofibrosis in myeloproliferative disease | |
| D47.9 | Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9970/1, 9931/3) | |
| D47.Z- | Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9960/3, 9970/1, 9971/3, 9931/3) | |
| D49.6, D49.7 | Neoplasm of unspecified behavior of brain, endocrine glands and other CNS | |
| D72.110 | Idiopathic hypereosinophilic syndrome [HES] | |
| D72.111 | Lymphocytic Variant Hypereosinophilic Syndrome [LHES] | |
| D72.118 | Other hypereosinophilic syndrome | |
| D72.119 | Hypereosinophilic syndrome [HES], unspecified | |
| R85.614 | Cytologic evidence of malignancy on smear of anus | |
| R87.614 | Cytologic evidence of malignancy on smear of cervix | |
| R87.624 | Cytologic evidence of malignancy on smear of vagina | |
1 Note: Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will CONTINUE to report these cases and code behavior as /3 (malignant).
NOTE: Cases with the codes listed below should be screened as registry time allows. Experience in the SEER registries has shown that using the supplemental list increases casefinding for benign brain and CNS, hematopoietic neoplasms, and other reportable diseases
A list of detailed and supplemental ICD-10-CM codes which may also be used for casefinding is available in APPENDIX M.
Follow this link for a casefinding list of reportable ICD-10 codes effective for years 2019 and before which includes a comprehensive list plus a supplemental list. https://seer.cancer.gov/tools/casefinding/
2. Pathology reports:
All pathology reports on both inpatients and outpatients should be reviewed for case reportability. Since most cancer patients have a biopsy or operative resection performed, nearly all of the reportable cases can be identified through pathology reports alone. Histologic diagnoses are based upon microscopic examination of tissue taken from such procedures as biopsy, frozen section, surgery, or D & C. Expand path report screening to include benign CNS tumors, beginning with 1-1-04 diagnoses. Check for cases of anal intraepithelial neoplasia, grade III (AIN III), ductal intraepithelial neoplasia 3 (DIN 3), vaginal intraepithelial neoplasia, grade III (VAIN III), vulvar intraepithelial neoplasia, grade III (VIN III), Laryngeal intraepithelial neoplasia III (LIN III), Lobular neoplasia grade III (LN III)/lobular intraepithelial neoplasia grade III (LIN III), Penile intraepithelial neoplasia, grade III (PeIN III), and Squamous intraepithelial neoplasia III (SIN III) excluding cervix.
NOTE: Path reports may be the best source for finding cases of VIN, VAIN, and AIN (8077/2) and DIN (8500/2).
3. Cytology reports:
All cytology reports for both inpatients and outpatients should be reviewed for case reportability. Cytologic diagnoses are based upon microscopic examination of cells as contrasted with tissues. Included are smears from sputum, bronchial bushings, bronchial washings, tracheal washings, prostatic secretions, breast secretions, gastric fluid, spinal fluid, peritoneal fluid, pleural fluid, and urinary sediment. Cervical and vaginal smears are common examples.
4. Autopsy reports.
5. Radiation Therapy Department logs.
6. Medical Oncology Department logs.
7. Outpatient Department:
New patient registration rosters, clinic appointment books, surgery schedules, diagnostic imaging, and billing departments are additional casefinding sources.
8. Alpha listing of previously included cases:
Casefinding cannot be considered complete until the CPDMS.net accession list and any previous registry accession lists have been checked to be sure that this is a new patient or a new primary.
Creating and Maintaining a Nonreportable List
In the course of routine casefinding activities, cases which are found to be nonreportable by your hospital should be added to a nonreportable list. The list should consist of each patient’s name, DOB, SSN, medical record number, the type/site of cancer, and a brief explanation of why the case is not reportable to the hospital registry (i.e., "patient was seen for consult only, no dx or tx," or "patient originally diagnosed prior to reference date"). A well-maintained nonreportable list will save registrars time by preventing them from reviewing a chart multiple times to check on a particular primary that does not need to be abstracted. The list can be invaluable during casefinding audits by allowing quick resolution of possible missed cases. It is also helpful during the death clearance process.
Bear in mind that cases which are not reportable by your hospital, but which ARE reportable to KCR (see Case Reporting Requirements) should be sent to the central registry to be abstracted there. These may include:
• A specimen from an outside doctor’s office which was sent to your hospital’s path lab
• Any case that was diagnosed and/or treated only in a nonhospital facility
• A Kentucky resident who was initially diagnosed or treated out of state
Overview
Content Tools
Activity